抗感染、抗肿瘤药物活性及分子机制。

（1）国家卫健委十三五“新药创制”科技重大专项，I类新药抗真菌多肽PL-18和抗耐药菌多肽Cbf-14临床前研究，2019ZX09721001-004-005，244万元，2019-2020。

（2）国自然面上项目，基于MCR-1修饰LPS介导的细菌免疫逃逸探讨新结构多肽MSI-1抗多黏菌素耐药感染的机制（82173863），55万元，2021-2024。

（3）国自然面上项目，基于多靶点的多肽抗耐药性细菌感染的机制研究（81673483），45万元，2017-2020。

（4）江苏省自然科学基金面上项目，基于LPS识别模式的多肽调节mcr-1抗多粘菌素耐药菌感染的宿主免疫防御机制, BK20201327,10万元，2020-2023。

(1) Wang L, Liu M, Qi Y, Wang J, Shi Q, Xie X, Zhou C*, Ma L*. hsdSA regulated extracellular vesicle-associated PLY to protect Streptococcus pneumoniae from macrophage killing via LAPosomes. Microbiol Spectr. 2024 Jan 11;12(1):e0099523. doi: 10.1128/spectrum.00995-23. Epub 2023 Nov 29.

(2) Xinyue Ye, Jian Wang, Pengfei Xu, Xiaoqian Yang, Qixue Shi, Genyan Liu, Zhaoshi Bai*, Changlin Zhou*, Lingman Ma*. Peptide MSI-1 inhibited MCR-1 and regulated outer membrane vesicles to combat immune evasion of Escherichia coli. Microbial biotechnology. 2023 Sep;16(9):1755-1773

(3) Chenyu Zhou, Meiling Jiang, Xinyue Ye, Xiaoyun Liu, Wenxuan Zhao, Lingman Ma, Changlin Zhou*. Antibacterial Activities of Peptide HF‑18 Against Helicobacter pylori and its Virulence Protein CagA. International Journal of Peptide Research and Therapeutics. 2022 Mar; 28(2)

(4) Lingman Ma1, XinyueYe1, Pengbo Sun, Pengfei Xu, Liping Wang, Zixiang Liu, Xiaowei Huang, Zhaoshi Bai, Changlin Zhou. Antimicrobial and antibiofilm activity of the EeCentrocin 1 derived peptide EC1-17KV via membrane disruption. Ebiomedicine. 2020 May; 55: 102775

(5) Lingman Ma1, Xin Xie1, Hanhan Liu, Ya Huang, Haomin Wu, Meiling Jiang, Pengfei Xu, Xinyue Ye, Changlin Zhou*. Potent antibacterial activity of MSI-1 derived from the magainin 2 peptide against drug-resistant bacteria. Theranostics. 2020 Jan 1;10(3):1373-1390

(6) Meiling Jiang, Xiaoqian Yang, Haomin Wu, Ya Huang, Jie Dou, Changlin Zhou*, Lingman Ma*. An active domain HF-18 derived from hagfish intestinal peptide effectively inhibited drug-resistant bacteria in vitro/vivo. Biochemical Pharmacology. 2020 Feb; 172:113746

(7) Xin Xie1, Lingman Ma1, Yiran Zhou 1, Wen Shen, Duiyue Xu, Jie Dou, Baiyong Shen*, Changlin Zhou*. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. Carbohydrate Polymers. 2019 Dec 1; 225: 115223

(8) Wei Kang, Hanhan Liu, Lingman Ma, Mengxiao Wang, Shanshan Wei, Pengbo Sun, Meiling Jiang, Min Guo, Changlin Zhou*, Jou Dou*. Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids. European Journal of Pharmaceutical Science. (2017), 105:169-177

(9) Xin Xie, Yiran Zhou, Xue Wang, Jian Guo, Jingwen Li, Hongye Fan, Jie Dou, Baiyong Shenb*, Changlin Zhou*. Enhanced antitumor activity of gemcitabine bypolysaccharide-induced NK cell activation and immune cytotoxicityreduction in vitro/vivo. Carbohydrate Polymers, 173 (2017) 360–371

(10) Lingman Ma, Yanrong Wang, Mengxiao Wang, Yuwei Tian, Wei Kang, Hanhan Liu, Hui Wang, Jie Dou^*, Changlin Zhou^*. Effective antimicrobial activity of Cbf-14, derived from a cathelin-like domain, against penicillin-resistant bacteria. Biomaterials (2016). 87: 32-45

(11) Mengyun Ke, Hui Wang, Min Zhang, Yuwei Tian, Yizhou Wang, Bing Li, Jie Yu, Jie Dou, Tao Xi, Changlin Zhou*. The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochemical Pharmacology, 2014, 89: 119-130